Eleven medicines backed for EU approval
Recommendations include the first antibody-drug conjugate for multiple myeloma patients with limited treatment options
Read More
Tag: bevacizumab
Eight medicines leap towards EU approval
The recommendations include a conditional approval for Gilead’s Veklury (remdesivir) for COVID-19
Read More
Roche’s Tecentriq/Avastin combo wins US approval
Tecentriq in combination with Avastin is the first and only cancer immunotherapy regimen cleared to treat unresectable or metastatic liver cancer
Read More
Seven medicines leap closer to EU approval
The European Medicines Agency’s human medicines committee (CHMP) has put forward seven medicines for approval in the region.
Read More
High Court rejects Novartis, Bayer’s bid to outlaw off-label Avastin
Bayer and Novartis have lost a landmark case in the UK seeking to prevent the off-label use of Roche’s Avastin to treat wet AMD, a leading cause of sight loss in the elderly.
Read More
Biosimilar Avastin wins EU approval
European regulators have issued a green light for Amgen and Allergan’s Mvasi, marking the first biosimilar of Roche’s Avastin to be approved in the region.
Read More
AZ deepens ties with Myriad on Lynparza companion test
AstraZeneca has expanded its agreement with US group Myriad Genetics to identify women with advanced ovarian cancer most likely to benefit from its medicines.
Read More
Tecentriq/Avastin combo hits progression-free survival target
Roche unit Genentech has announced that a Phase III study assessing a combination of Tecentriq and Avastin for advanced or metastatic renal cell carcinoma achieved its co-primary endpoint of progression-free survival.
Read More
Avastin wins full green light for glioblastoma
Roche group Genentech has announced full US approval for Avastin for the treatment of adults with glioblastoma that progressed following prior therapy.
Read More
Ten new medicines leap towards EU approval
The European Medicines Agency’s Committee for Medicinal Products for Human Use has put 10 medicines forward for approval in the region, including new options for multiple sclerosis, eosinophilic esophagitis and eosinophilic asthma.
Read More
FDA considers Avastin as first-line ovarian cancer therapy
US regulators are reviewing a potential new indication for Avastin as a first-line option for advanced ovarian cancer, filed by Roche group Genentech.
Read More
US expands scope of Avastin in ovarian cancer
The US Food and Drug Administration has approved Roche-group Genentech’s application to market Avastin for patients with a specific type of ovarian cancer.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
